Skip to main content
Fig. 5 | Journal of Orthopaedic Surgery and Research

Fig. 5

From: m6A-modified circARHGAP12 promotes the aerobic glycolysis of doxorubicin-resistance osteosarcoma by targeting c-Myc

Fig. 5

m6A-modified circARHGAP12 enhanced the stability of c-Myc mRNA via m6A-dependent manner. A There was a remarkable m6A-modified loci in the circARHGAP12. B The RIP-PCR assay using the anti-m6A antibody was conducted in DOX-resistant OS cells (Saos-2/Dox, MG63/Dox). The circARHGAP12 level was tested in the immunoprecipitation of anti-m6A antibody. C The RIP-PCR assay using the anti-c-Myc antibody was conducted in DOX-resistant OS cells (Saos-2/Dox, MG63/Dox). The circARHGAP12 level was tested in the immunoprecipitation of anti-c-Myc antibody. D The RT-PCR assay was conducted in DOX-resistant OS cells (Saos-2/Dox, MG63/Dox). The c-Myc mRNA level was tested. E, F RNA stability analysis using Act D was conducted in DOX-resistant OS cells (Saos-2/Dox, MG63/Dox). The half-life time (t1/2) of c-Myc mRNA was calculated for c-Myc mRNA stability. Data were presented as means ± SD from three independent experiments. **p < 0.01, *p < 0.05

Back to article page